Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
interesting read could be foretelling of near and mid future.
https://www.marketwatch.com/story/cannabis-stocks-mostly-higher-after-major-rout-but-concerns-about-lack-of-profit-persist-2019-10-11
an explanation? interesting read. Could be foretelling of what is in store for future near and mid term.
https://www.marketwatch.com/story/cannabis-stocks-mostly-higher-after-major-rout-but-concerns-about-lack-of-profit-persist-2019-10-11
nice come back so far.
looks like this wants to go and visit Gene / Ivitf. going the same way.
appreciate the clarification thanks.
thanks for the reply.
You posted a message to my response and it appears to have been deleted, was that by you or the board.
you are referencing 2018 try looking into 2019
https://investorshub.advfn.com/Abattis-Bioceuticals-Corp-ATTBF-26115/
https://www.google.com/search?q=abattis+lawsuit&rlz=1C1CHBF_enCA840CA841&oq=ABATTIS&aqs=chrome.1.0j69i59l2j69i61j69i60l2.14293j0j7&sourceid=chrome&ie=UTF-8
This may be part of other peoples concerns
Think I'll go paint something and watch it dry, could be about as interesting as this today. Time will tell. Blue or green only colors I got. Oh well, sigh.
Reading Material:
MARIJUANA
Wall Street’s First Marijuana Stock Bull Gives Up and Slashes Tilray’s Price Target
By Bill Alpert
Sept. 3, 2019 11:35 am ET
Cowen & Co. analyst Vivien Azer was Wall Street’s first cannabis bull—and she was very bullish. She stuck to her $150 price target for Canadian producer Tilray (ticker: TLRY) long after other analysts conceded that Canada’s legal pot market had stumbled out of the starting gate. That $150 target was nearly triple the level of most peers.
Azer waved the white flag on Tuesday and cut Tilray’s (ticker: TLRY) target to $60. She also trimmed her target on Cronos Group (CRON) to C$17 (US$13). The rollout of recreational pot sales since Canada’s October 2018 legalization has been “muted,” she acknowledges in a set of reports, hampered by too few stores, product shortages and the prohibition of popular products like vapes and edibles. Retail prices for Canadian legal weed are 80% higher than the illicit stuff.
Azer started beating the drum for legal weed’s sales prospects in 2016, after visiting Colorado and seeing demand for cannabis that had become legal under that state’s law (while remaining illicit under U.S. federal law).
See our March interview with Azer: Here Are Wall Street’s First Pot Analyst’s Favorite Stocks
“[I]t is no surprise that cannabis trading multiples have retrenched this year,” she wrote, “and are down 43% on a market-cap weighted basis since April 1.”
With revenue growth weaker than her original forecasts, Azer says the stocks of Tilray and Cronos are commanding lower multiples. She had already cut her target for Canopy Growth (CGC) to C$48 from $82, after the company reported steep losses in its June 2019 quarter.
In her Tuesday notes, Azer maintains an upbeat tone—claiming that the hindrances on Canada’s pot sales will reverse and unleash sales. As stores open and the country allows novel products like vapes in 2020, cannabis industry sales will catch up with her forecast for countrywide sales of C$12 billion by 2025.
The collapse in Canadian pot stocks like Tilray, Canopy and Aurora Cannabis (ACB) makes them compelling values, she says, so she is maintaining her Outperform ratings on all three.
Tilray stock was up 2% in Tuesday morning trading, to US$26. A September 2018 blowout sent the stock to $300, in a brief Bitcoin-like mania. As recently as February 2019, it went for $100 a share. Cronos stock was off 1% in Tuesday trading, at US$10.90.
Azer’s partiality to Tilray became glaring as other analysts issued Hold ratings after the highly-valued company ran up large losses on weak pot sales. But Azer’s early advocacy of cannabis produced a great investment banking opportunity for her midsize brokerage firm. Cowen helped take Tilray public and even picked up a piece of the British Columbia-based pot producer. Cowen’s stake in Tilray gained $30 million in value during the stock’s September 2018 spike.
While admiring the greenfield sales opportunity for legal weed, Barron’s has been cautious about the Canada’s pot stocks since a March 2018 cover story.
Write to Bill Alpert at william.alpert@barrons.com
MARIJUANA
Wall Street’s First Marijuana Stock Bull Gives Up and Slashes Tilray’s Price Target
By Bill Alpert
Sept. 3, 2019 11:35 am ET
Cowen & Co. analyst Vivien Azer was Wall Street’s first cannabis bull—and she was very bullish. She stuck to her $150 price target for Canadian producer Tilray (ticker: TLRY) long after other analysts conceded that Canada’s legal pot market had stumbled out of the starting gate. That $150 target was nearly triple the level of most peers.
Azer waved the white flag on Tuesday and cut Tilray’s (ticker: TLRY) target to $60. She also trimmed her target on Cronos Group (CRON) to C$17 (US$13). The rollout of recreational pot sales since Canada’s October 2018 legalization has been “muted,” she acknowledges in a set of reports, hampered by too few stores, product shortages and the prohibition of popular products like vapes and edibles. Retail prices for Canadian legal weed are 80% higher than the illicit stuff.
Azer started beating the drum for legal weed’s sales prospects in 2016, after visiting Colorado and seeing demand for cannabis that had become legal under that state’s law (while remaining illicit under U.S. federal law).
See our March interview with Azer: Here Are Wall Street’s First Pot Analyst’s Favorite Stocks
“[I]t is no surprise that cannabis trading multiples have retrenched this year,” she wrote, “and are down 43% on a market-cap weighted basis since April 1.”
With revenue growth weaker than her original forecasts, Azer says the stocks of Tilray and Cronos are commanding lower multiples. She had already cut her target for Canopy Growth (CGC) to C$48 from $82, after the company reported steep losses in its June 2019 quarter.
In her Tuesday notes, Azer maintains an upbeat tone—claiming that the hindrances on Canada’s pot sales will reverse and unleash sales. As stores open and the country allows novel products like vapes in 2020, cannabis industry sales will catch up with her forecast for countrywide sales of C$12 billion by 2025.
The collapse in Canadian pot stocks like Tilray, Canopy and Aurora Cannabis (ACB) makes them compelling values, she says, so she is maintaining her Outperform ratings on all three.
Tilray stock was up 2% in Tuesday morning trading, to US$26. A September 2018 blowout sent the stock to $300, in a brief Bitcoin-like mania. As recently as February 2019, it went for $100 a share. Cronos stock was off 1% in Tuesday trading, at US$10.90.
Azer’s partiality to Tilray became glaring as other analysts issued Hold ratings after the highly-valued company ran up large losses on weak pot sales. But Azer’s early advocacy of cannabis produced a great investment banking opportunity for her midsize brokerage firm. Cowen helped take Tilray public and even picked up a piece of the British Columbia-based pot producer. Cowen’s stake in Tilray gained $30 million in value during the stock’s September 2018 spike.
While admiring the greenfield sales opportunity for legal weed, Barron’s has been cautious about the Canada’s pot stocks since a March 2018 cover story.
Write to Bill Alpert at william.alpert@barrons.com
nice come back at open
looks like more down, not a good sign on the day of earnings release. Pre market is at 1.61. EMH
sorry posted in the wrong forum. Self deleted.
General info and to get a feeling how the investors feel about emh. And yes listen to the conf call. One of the questions asked so they may be interested in feed back as well. Two days.
Did anyone else get a phone call from emh today?
anyone have news or idea's why today we reverse. love it!
The emhtf 52 wk low was 1.48 maybe it will turn around here or close to here, if not I see nothing to stop the drop until 1.00 for emhtf
Edit: that's using a 2 year chart.
Oct 17th may be the next hyped driving force...when the second part of the Canadian legalization process is to be completed. little more than 2 1/2 months away... but in the meantime possible more down side than upside.
https://www.prnewswire.com/news-releases/canada-braces-for-second-round-of-cannabis-product-legalizations-300886339.html
Just broke the 52 week low on EMH, may be time to drop this one till it finds a base again. Where at is the question, Like the limbo...
How Low Can You Go..
nice recovery so far.
Just hope they are not going to follow Gene / Ivitf.
0.16 away from EMH 52 wk low.
getting closer to the 52 wk low emhtf 1.48
edit:
Planning to buy at that level.
looks like emhtf wants to revisit 1.48 the 52 week low.
I am hoping for good news on 30th May earnings report (after hrs). And explanations as well as more good news during the conference call on 31st. Still have some powder for a good report.
fingers crossed.
OFFICIAL: earnings conference call 31 may
https://ir.emeraldhealth.ca/news-releases/news-release-details/emerald-health-therapeutics-hold-conference-call-first-quarter
Hey Dodger1, what I see is what I posted earlier sometime back. The Industry geared up before legalization, it pumped the market up filled everyone's head with how much they could make in a short period of time, then it slipped as legalization was deferred to a later date, ( July to Oct.) This was the first indication of over valuation of company's. Then after legalization it dropped more ( as days went on after the initial pop for some) This sector has been overvalued for a while, it is now starting to show direction now but still has a ways to go. After the end qtr 2018 look what happened to the valuation of most company's now 1st qtr financial's. It will take a few more for this to turn around and show true value, however it could be a good time to invest if you don't have any need for instant gratification, long term only. Some if you want are good for day trading at the moment. (while you wait for it to go) some are to be avoided. Doing as you are...DD and setting goals is now the way to go, but most I see is sell the news events. vff is doing well but they are also up and down. Look at a couple of the big ones Tlry and follow what happened to it's sp. Same can be applied to all these MJ stocks. More time needed to get the market in place. (find it's niche and its footing)
don't know if this helped but Not much else can be said.
True if I were buying the illegal stuff, but the prices I showed were for legal flower. I also have medical cert for my stuff. But I use oil personally, and the dispensary I use I get receipts for my prescription costs so I can claim on I Tax as medical costs. So far so good. Can't actually smoke the stuff, lungs wont accept it. Will see end this year as to how it works out for I Tax.
cheers all.
Still on side watching and waiting to re-buy, which is why I don't post much.
If your paying that much per gram of weed your getting gouged. I can still get good weed for 50 per 1/4 oz that is 7.5 gr. Or 169.00 for mail order 28 gr (1 full oz) = 6.03 per gr. so government wants you to pay 13.85 for what??? 13.85 X 28 gr = 387.80 Wow. Google for weed and see what you get for suppliers. WARNING: not all will be legal. but definitely...shop around.
https://www.invictus-md.com/post/421 in case no one saw it on their web site or news.